RYTM 56.12 (+1.15%)
US76243J1051BiotechnologyBiotechnology

Rhythm Pharmaceuticals (RYTM) Stock Highlights

56.12 | +1.15%
2024-12-21 02:30:27
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The companys product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Statistics

Range Today
55.47 58.16
Volume Today 1.1M
Range 1 Year
35.17 68.58
Volume 1 Year 138.81M
Range 3 Year
3.04 68.58
Volume 3 Year 598.77M
Range 10 Year
3.04 68.58
Volume 10 Year 860.82M

Highlights

Market Capitalization 4.14B (mid)
Floating Shares 45.16M
Current Price 56.12
Price To Earnings -13.86
Price To Revenue 36.38
Price To Book 367.92
Earnings Per Share -4.55
Payout Ratio 0%

Performance

Latest +1.15%
1 Month -6.44%
3 Months +2.88%
6 Months +36.48%
1 Year +22.72%
3 Years +455.09%
5 Years +140.34%
10 Years +120.51%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.